Compare Biogen Inc (BIIB) vs Gigacloud Technology Inc (GCT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Gigacloud Technology Inc — how do they compare? Biogen Inc trades at $206.5 (market cap $30.13B), while Gigacloud Technology Inc trades at $51.32 (market cap $1.84B). The key difference: Biogen Inc is far larger — about 16.4× Gigacloud Technology Inc's market cap. Which is the better fit depends on your goals.
| BIIB | GCT | |
|---|---|---|
Market Cap | $30.13B | $1.84B |
Sector | Health | Technology |
52-Week High | $216.63 | $53.25 |
52-Week Low | $128.93 | $25.44 |
Enterprise Value | $37.20B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
GCT trades at $51.25, down 0.78% on the day, with strong technical momentum showing bullish moving averages and key resistance at $53. The company demonstrates robust fundamentals with Q2 2026 EPS of $1.16 beating estimates by 29%, maintaining consistent earnings beats and 10.65% net margins. Revenue growth accelerated to 28% in Q2 2026, reaching $1.5B annually, while cash flow generation remains healthy at $120M net cash flow for 2025.
GCT presents a compelling growth story with attractive valuation at 12.25 P/E ratio and strong analyst support (67% buy ratings). Key risks include competitive pressures in furniture logistics and potential margin compression from expansion costs. The stock's technical overbought condition (RSI above 84) suggests near-term consolidation may precede further upside driven by execution on European expansion and New Classic integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →
